Choosing the best treatment for blood cancer is often one of the most difficult decisions doctors face. Every patient is different, and modern cancer care requires doctors to understand genetics, previous treatments, overall health, and constantly changing medical research.
A newly developed artificial intelligence assistant called HemaGuide may help doctors make these complex decisions more quickly and accurately.
Scientists from the German Cancer Research Center, the HI-STEM Stem Cell Institute, and Heidelberg University Hospital developed the system and reported their results in Nature Medicine.
Blood cancers include diseases such as leukemia, lymphoma, and multiple myeloma. These illnesses often require personalized treatment plans because different patients can respond very differently to the same medicine.
Many hospitals rely on expert tumor boards, where specialists meet to discuss difficult cases. Unfortunately, not every hospital has access to these highly trained teams.
HemaGuide was created to bring some of this expert knowledge directly to treating physicians. The AI examines doctors’ notes, reviews current treatment guidelines, compares similar patient cases, and searches recent medical research before suggesting possible treatments.
It also explains why each recommendation was made, helping doctors understand the reasoning behind its advice.
One particularly valuable feature is the system’s ability to examine genetic changes found in tumors. Modern cancer treatment increasingly depends on identifying these changes because some patients can benefit from highly targeted medicines. HemaGuide performs this analysis in less than a minute, greatly reducing work that previously required hours of expert review.
Privacy was another major design goal. Because HemaGuide operates on hospital computers, sensitive patient records remain inside the hospital instead of being sent elsewhere.
To evaluate its performance, researchers compared the AI with experienced blood cancer specialists.
Across hundreds of real tumor board cases involving both common and rare blood cancers, HemaGuide reached treatment recommendations that matched expert decisions about 82% to 83% of the time. Doctors in training also made better decisions when using the AI, approaching the performance of experienced specialists.
The researchers stressed that HemaGuide is not intended to replace physicians. Instead, it acts like an additional expert sitting beside the medical team. Doctors continue to make all final decisions after considering the AI’s recommendations together with each patient’s individual circumstances.
The results are encouraging because they suggest AI could reduce differences in cancer care between large medical centers and smaller hospitals. Patients living far from specialized cancer centers may eventually gain access to more expert-level advice without needing to travel.
Although the study demonstrates impressive accuracy, further clinical research is still required. Future trials will test whether using HemaGuide improves patient survival, quality of life, and overall healthcare outcomes.
If these benefits are confirmed, AI assistants like HemaGuide could become valuable tools for supporting doctors while keeping patients at the center of every treatment decision.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more health information, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
Source: German Cancer Research Center (DKFZ).
